Sanofi (SNY) - Stock Analysis
Last updated: Mar 9, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Sanofi shows strong regulatory and pipeline momentum with recent FDA approvals and fast-track designations, double-digit sales growth, margin improvements, and an ongoing âŹ5B share buyback. Technicals indicate a bullish pattern near resistance, making it a hot idea with evident catalysts.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High profitability ⢠Strong cash flow ⢠Moderate leverage Sanofi is a highly profitable, cash-generative pharma with moderate leverage and an attractive dividend, but reliant on large intangibles and with limited short-term liquidity that could constrain flexibility.
Price Behavior
Key Price Behavior Insights: ⢠Short-term downtrend ⢠Below mid-$40s ⢠Support at $44.5 Support Level: $44.5 Resistance Level: $47â$49.25 SNY is in a clear short-term downtrend over the last month, falling about 6% from ~$47.49 to $44.55 and trading below the recent midâ$40s average, with nearâterm support at $44.5 and resistance in the midâ$47sâ$49.25 area.
Sentiment & News
Key News Insights: ⢠CEO replacement ⢠Dupixent dependency ⢠Regulatory momentum Sanofi faces a governance shake-up and execution risk after a surprise CEO change and board refresh amid strong Dupixent reliance and recent regulatory wins that leave the stock undervalued but volatile.
AI Summary
Sanofi has shifted from a defensive dividend stalwart to a midâcycle, higherâupside but executionâdependent growth storyâdriven by Dupixent-led launches and boltâon M&Aâso investors should now trade it on program/regulatory outcomes and integration milestones rather than yield stability. Key actionable focus: monitor Dupixent growth trajectory, upcoming lateâstage readouts/PDUFAs and Blueprint integration/cashâflow cadence over the next two quarters to judge whether to overweight or pare exposure.
Description
Sanofi is a Paris-based multinational pharmaceutical company that researches, develops, manufactures and commercializes medicines, vaccines and consumer healthcare products worldwide. Its operations are organized into pharmaceuticals, vaccines and consumer healthcare businesses, offering treatments across specialty care, diabetes, cardiovascular and established medicines, as well as pediatric and adult vaccines and a range of over-the-counter health and personal care products. The company maintains several research collaborations and has a pipeline of pharmaceutical products and vaccines in development.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Oct 20 | Oct 27 | SNY | Sanofi | Sanofi shows strong regulatory and pipeline momentum with recent FDA approvals and fast-track designations, double-digit sales growth, margin improvements, and an ongoing âŹ5B share buyback. Technicals indicate a bullish pattern near resistance, making it a hot idea with evident catalysts. | Closed | +3.4% |